This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    Promitil
Previous Study | Return to List | Next Study

Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.

This study is currently recruiting participants.
See Contacts and Locations
Verified July 2017 by Lipomedix Pharmaceuticals Inc.
Sponsor:
Information provided by (Responsible Party):
Lipomedix Pharmaceuticals Inc.
ClinicalTrials.gov Identifier:
NCT01705002
First received: October 8, 2012
Last updated: July 4, 2017
Last verified: July 2017
  Purpose

This is a Phase I, multi-center, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients with Solid Tumors. The study comprised of:

Escalated cohorts A-H: 27 male or female participants, ages 18-80, BMI 18-36 diagnosed with inoperable, recurrent or metastatic malignant solid tumors, deemed incurable, and who have failed to respond to standard therapy or for whom no standard therapy is available. Eligible subjects will be assigned, successively in order of accrual, to one of eight cohorts, to receive escalating doses of intravenously infused PROMITIL. PROMITIL will be administered as an intravenous infusion. Dose escalation will only proceed in the absence of dose-limiting toxicity (DLT). For this purpose, each cohort will only begin its first cycle of PROMITIL when the cohort preceding it has successfully completed its first 4-week cycle without any signs of DLT.

Expanded cohort: 17 adult patients with metastatic CRC. The purpose of this expanded cohort is to further evaluate the safety of Promitil and to search for signs of antitumor activity of Promitil in this specific patient population.

Combination Cohort (Promitil concomitantly with Capecitabine): 23 adult patients with metastatic CRC.

Triple combination Cohort: 13 additional subjects with metastatic CRC, received combination of Promitil concomitantly with Bevacizumab (5 mg/kg) on day 1 of a 28 day cycle and Capecitabine on days 1-14 of a 28 day cycle.

3 weekly cohort- 9 subjects with metastatic CRC will receive Promitil and Bevacizumab (7.5 mg/kg) on day 1 of a 21 day cycle.


Condition Intervention Phase
Cancer Solid Tumor Metastatic Colorectal Cancer (mCRC) Drug: Promitil Drug: Capecitabine Drug: Bevacizumab Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors.

Resource links provided by NLM:


Further study details as provided by Lipomedix Pharmaceuticals Inc.:

Primary Outcome Measures:
  • Maximal Tolerated Dose (MTD) of PROMITIL [ Time Frame: First cycle of treatment (4 weeks) ]
    Only DLTs occurring during the first cycle of treatment for each participant will determine MTD endpoint

  • Dose Limiting Toxicity (DLT) of PROMITIL [ Time Frame: First cycle of treatment (4 weeks) ]
  • Pharmacokinetic (PK) profile of PROMITIL [ Time Frame: 3 cycles of treatment (12 weeks) ]
    PK assessments will monitor plasma levels of MLP and metabolite (MMC), as well as PK parameters (Cmax, AUC0-t, AUC 0-∞, MRT, t½ , Kel, Cl, VD).


Secondary Outcome Measures:
  • Anti-tumor responses to the delivered PROMITIL regimens [ Time Frame: 12 months ]
  • Toxicity profile of PROMITIL [ Time Frame: 3 cycles of treatment (12 weeks) ]

Estimated Enrollment: 90
Study Start Date: October 2012
Estimated Study Completion Date: September 2018
Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort A: Promitil 0.5 mg/kg
Three treatment cycles, intravenous infusion of Promitil
Drug: Promitil
2 mg/kg dose IV
Experimental: Cohort B: Promitil 1.0 mg/kg
Three treatment cycles, intravenous infusion of Promitil
Drug: Promitil
2 mg/kg dose IV
Experimental: Cohort C: Promitil 1.5 mg/kg
Three treatment cycles, intravenous infusion of Promitil
Drug: Promitil
2 mg/kg dose IV
Experimental: Cohort D: Promitil 2.0 mg/kg
Three treatment cycles, intravenous infusion of Promitil
Drug: Promitil
2 mg/kg dose IV
Experimental: Cohort E: Promitil 2.5 mg/kg
Three treatment cycles, intravenous infusion of Promitil
Drug: Promitil
2 mg/kg dose IV
Experimental: Cohort F: Promitil 3.0 mg/kg
Three treatment cycles, intravenous infusion of Promitil
Drug: Promitil
2 mg/kg dose IV
Experimental: Cohort G: Promitil 3.5 mg/kg
Three treatment cycles, intravenous infusion of Promitil
Drug: Promitil
2 mg/kg dose IV
Experimental: Cohort H: Promitil 4.0 mg/kg
Three treatment cycles, intravenous infusion of Promitil
Drug: Promitil
2 mg/kg dose IV
Experimental: Expanded Cohort

Patients treated with the selected RP2D of PROMITIL (3 mg/kg) intravenously administered on their first cycle and reduced dose of 2 mg/kg from cycle 2 and onwards.

Only for mCRC patients.

Drug: Promitil
2 mg/kg dose IV
Experimental: Combination Cohort

Patients treated with one cycle of 2.5mg/kg Promitil day 1 together with Capecitabine 1,000 mg bid po days 1-21 followed by two cycles of 2.0 mg/kg Promitil day 1 together with Capecitabine 1,000 mg bid po days 1-21, at four-week intervals.

Only for mCRC patients.

Drug: Promitil
2 mg/kg dose IV
Drug: Capecitabine
1000 mg dose BID PO for days 1-21 for Combination Cohort and on day 1-14 on Triple combination Cohort
Other Name: Xeloda
Experimental: Triple combination Cohort

Patients treated with one cycle of 2mg/kg Promitil I.v and 5 mg/kg Bevacizumab i.v on day 1 together with Capecitabine 1,000 mg bid p.o days 1-14 at four-week intervals.

Only for mCRC patients.

Drug: Promitil
2 mg/kg dose IV
Drug: Capecitabine
1000 mg dose BID PO for days 1-21 for Combination Cohort and on day 1-14 on Triple combination Cohort
Other Name: Xeloda
Drug: Bevacizumab
for Triple combination cohort an IV dose of 5 mg/kg on day 1 at 4 week interval. For the 3 weekly cohort an IV dose of 7.5 mg/kg at 3 week interval.
Other Name: Avastin
Experimental: 3 Weekly Cohort

Patients treated with one cycle of 2mg/kg Promitil I.v and 7.5 mg/kg Bevacizumab i.v on day 1 together at three-week intervals.

Only for mCRC patients.

Drug: Promitil
2 mg/kg dose IV
Drug: Bevacizumab
for Triple combination cohort an IV dose of 5 mg/kg on day 1 at 4 week interval. For the 3 weekly cohort an IV dose of 7.5 mg/kg at 3 week interval.
Other Name: Avastin

Detailed Description:

For all cohorts, PROMITIL will be administered as an intravenous infusion at an initial rate of 0.25mg/min followed by gradual increase to a maximal rate of 2mg/min until completion of dosing, if absence of infusion reactions is established and in line with most updated version of IFU available for this study.

For each subject, subsequent dosing will take place 28 days after the previous treatment, provided they are deemed fit to be dosed again.

Patients will return to the study center on days 8, 15, 22 of cycle 1, and on day 15 of cycles 2 and 3, for monitoring assessments.

All patients will be followed-up for survival and post-Promitil treatment. Patients who did not received 3 cycles of PROMITIL will be followed up only until PD.

For the 3 weekly cohort Promitil will be administered at 3 week interval together with Bevacizumab (7.5 mg/kg). Patients will return to the study center on days 8 and 15 of cycle 1, and on day 15 of cycles 2 and 3, for monitoring assessments.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients diagnosed with inoperable, recurrent or metastatic malignant solid tumors, deemed incurable, and who have either:

    • Failed to respond to standard therapy or
    • For whom no standard therapy is available or
    • Refuse to receive standard therapies
  2. Histologically or cytologically confirmed diagnosis of solid tumor on file.
  3. Age 18-80 years
  4. BMI: 18-36
  5. ECOG Performance Status ≤ 2
  6. Estimated life expectancy of at least 3 months
  7. Adequate bone marrow function (an absolute neutrophil count ≥1500/mm3, hemoglobin ≥9.5 g/dl, HgbA1C≤7%, and a platelet count ≥100,000/mm3(
  8. Adequate liver function (serum bilirubin ≤2.0 mg/100 ml; alanine aminotransferase ≤2× ULN)
  9. Adequate renal function (serum creatinine ≤1.5 mg/100 ml or creatinine clearance ≥45 ml/min/1.73m2)
  10. No prior intravenous treatment with Mitomycin-C either alone or in combination
  11. No other myelosuppressive treatment within 4 weeks before start of the study drug.
  12. No other anti-cancer treatment within 2 weeks before start of the study drug
  13. No prior extensive radiotherapy (e.g., whole pelvis total neuroaxis or greater than 50% of neuroaxis, whole abdomen, whole body or half-body) or bone marrow transplantation with high dose chemotherapy and/or total body irradiation. Re-irradiation of a field in abdomen/pelvis will be considered as extensive radiotherapy, excluding such patients from the study.
  14. Women of child bearing potential practicing an acceptable method of birth control.
  15. Understanding of study procedures and willingness to comply for the entire length of the study and to give written informed consent.
  16. Additional criteria only for the Expanded Cohort and both Combination cohorts: Patients with histologically or cytologically confirmed recurrent and/or metastatic measurable or nonmeasurable CRC, with tissue or cytological diagnosis of cancer on file.
  17. Additional criteria only for the Expanded Cohort and both Combination cohort: Patients who demonstrated either progression or intolerance when treated with irinotecan and fluopyrimidine-based chemotherapy, and, in the case of K-ras wild type tumors, anti-EGFR antibodies (Cetuximab, Panitumumab). Prior treatment with oxaliplatin or bevacizumab is allowed but not required.
  18. Additional criteria only for the Expanded Cohort and both Combination cohorts: A ≥28 day treatment-free interval between last chemotherapeutic treatment and first treatment with Promitil, with the exception of Capecitabine and biological therapies, where 14-day treatment-free intervals suffice. this is also relevant for patients in the Combination Cohort that are currently taking Capecitabine prior to enter the study).
  19. Additional criteria for the Triple Combination Cohort with bevacizumab only: Prior exposure to oxaliplatin should have terminated at least 6 months before start of PROMITIL, whether given as adjuvant therapy or as therapy for metastatic disease.
  20. Additional criteria for the triple Combination Cohort with bevacizumab only: A ≥ 28 day treatment-free interval from last bevacizumab treatment

Exclusion Criteria:

  1. Known hypersensitivity to the study drug or to any of its components
  2. CHF (NYHA = Class IV) or LVEF≤40%
  3. COPD > Stage 3 (FEV1<50%, FEV1/FVC<70%);
  4. Cirrhosis (Child-Pugh Class C score);
  5. Serum Albumin level < 3 g/dl
  6. Any other severe concurrent disease which in the judgment of the investigator would make the subject inappropriate for entry into this study
  7. History of human immunodeficiency virus (HIV) infection
  8. History of chronic active hepatitis including subjects who are carriers of hepatitis B virus (HBV) or hepatitis C virus (HCV).
  9. Presence of uncontrolled infection.
  10. Evidence of active bleeding or bleeding diathesis
  11. Brain metastases in symptomatic patients requiring ≥4 mg dexamethasone/day. However, patients with treated brain metastases by surgery or radiation who are stable and symptom-free (<4 mg dexamethasone/day) for a minimum period of 4 weeks post-treatment are eligible.
  12. Pregnant or lactating
  13. Treatment with other investigational drugs within 14 days of start of the study drug for non-myelosuppressive agents, and within 28 days of start of the study drug for myelosuppressive agents.
  14. Additional criteria for the Combination cohorts: Uncontrolled ascites (defined as 2 or more palliative taps in the last 30 days before screening).
  15. Additional criteria for the Combination cohorts with bevacizumab only: uncontrolled clinically significant cardiac disease, hypertension, arrhythmias, or angina pectoris; acute myocardial infarction or cerebrovascular accident within 12 months of initiation of PROMITIL treatment.
  16. Additional criteria for the Combination cohorts with bevacizumab only: Any contraindication for treatment with Bevacizumab (e.g active bleeding, recent extensive surgery).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01705002

Contacts
Contact: Alberto Gabizon, Prof. +972 77 9055361 alberto.gabizon@lipomedix.com
Contact: Patricia Ohana, Dr. +972-2- 5866177 patricia.ohana@lipomedix.com

Locations
Israel
Rambam Health Care Campus Recruiting
Haifa, Israel
Contact: Ruth Perets, Dr.       ru_perets@rambam.health.gov.il   
Principal Investigator: Ruth Pererts, Dr.         
Shaare Zedek Medical Center Recruiting
Jerusalem, Israel
Contact: Esther Tahover, MD    +972-50-7163123    esthert@hadassah.org.il   
Contact: Novatrials CRO Noga Brunicki    +972 52-4532325    noga@novatrials.com   
Principal Investigator: Esther Tahover, MD         
Chaim Sheba Medical center Active, not recruiting
Ramat Gan, Israel
Tel-Aviv Sourasky Medical Center Completed
Tel-Aviv, Israel, 64239
Sponsors and Collaborators
Lipomedix Pharmaceuticals Inc.
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Lipomedix Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT01705002     History of Changes
Other Study ID Numbers: PROMITIL-01
Study First Received: October 8, 2012
Last Updated: July 4, 2017

Keywords provided by Lipomedix Pharmaceuticals Inc.:
phase 1
dose escalating
prodrug
mitomycin C
Capecitabine

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Bevacizumab
Capecitabine
Mitomycins
Mitomycin
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic
Alkylating Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on September 21, 2017